The record draws on a substantial number of SEC EDGAR filings: an SC TO-T published June 2, 2025; a filing of unknown form type published May 16, 2025; two 8-K filings both published May 16, 2025 and an additional 8-K published July 1, 2025; a second unknown-form filing published May 16, 2025; and an SC 14D9 published June 2, 2025. The deal's status is closed, indicating the tender offer was completed.
The facts block names two financial advisors, each designated as lead on their respective side. Goldman Sachs & Co. LLC acted as exclusive financial advisor to BioMarin, the acquirer, while Cooley LLP served as BioMarin's legal counsel, per the source language that these two firms were advising the acquirer in tandem. On the target side, Centerview Partners LLC acted as exclusive financial advisor to Inozyme, with Goodwin Procter LLP serving as Inozyme's legal counsel, as stated in the corresponding source sentence. These advisor-role pairings (financial advisor plus legal counsel per side) recur multiple times across the underlying source documents, reflecting that the same relationship was reported in more than one filing.
On the legal side, Cooley LLP is confirmed as legal advisor to the acquirer, BioMarin, and Goodwin Procter LLP is confirmed as legal advisor to the target, Inozyme, consistent with the pairings described above.
Beyond identifying the transaction as a tender offer with a $270,000,000 disclosed value, the facts block does not provide additional detail on the offer price per share, the proration mechanics, or any other structural terms of the tender offer.
Notably absent from the record are details such as the specific per-share tender price, the percentage of shares sought or tendered, and any conditions to closing. Since the deal's status is listed as closed, the disclosed value and advisor roles described above represent the full extent of what the source material provides about how the transaction concluded.